GRC 10389

GRC 10389 is an orally bioavailable small molecule inhibitor of phosphodiesterase 4 (PDE4), developed by Glenmark Pharmaceuticals. PDE4 is a key enzyme involved in the degradation of cyclic adenosine monophosphate (cAMP) within inflammatory and immune cells. By inhibiting PDE4, GRC 10389 elevates intracellular cAMP levels, which subsequently activates protein kinase A and inhibits the release of pro-inflammatory cytokines such as TNF-alpha and interleukin-12. This anti-inflammatory profile was primarily investigated for the treatment of respiratory conditions, specifically Chronic Obstructive Pulmonary Disease (COPD). While the compound demonstrated potency in early-stage clinical trials, its development appears to have stalled or been discontinued in favor of other pipeline candidates.